Nexentis Technologies Inc. has monetized a portion of its investment in the Melz solar PV project in Germany, securing immediate liquidity at a total project valuation of $14.5 million. The company signed an addendum to the loan and partnership agreement with Solterra Renewable Energy Ltd. and other lenders, facilitating early partial repayments and the sale of profit rights. This valuation represents a significant premium to Nexentis's initial investment in the 115 MWp project.

The transaction follows a share purchase agreement under which Solterra and its assets are being sold to Sunflower Sustainable Investments Ltd. As a result, Solterra is making early partial loan repayments and reducing profit rights. The addendum provides Nexentis with current cash flow while preserving upside potential through remaining profit rights and an option for a full exit based on an independent valuation upon the project achieving Ready-to-Build (RTB) status.

Transaction Breakdown

The group of lenders, in which Nexentis holds the majority share, provided a total commitment of approximately $2.95 million to advance the Melz project to the RTB stage. Nexentis's portion of this commitment accounted for approximately $2.18 million. Under the terms of the addendum, Nexentis will receive several payments totaling $267,000.

The Melz project, with a capacity of approximately 111-115 MWp, continues to advance in its development phase. The transaction valuation of $14.5 million equates to approximately $120,000 per MW. Nexentis retains the option to purchase the remaining profit rights when the project reaches RTB status, subject to an independent valuation by a Big 4 accounting firm.

Nexentis Technologies Inc. owns 100% of MitoCareX Bio Ltd, a drug discovery company, and has adopted an investment strategy focused on European renewable energy assets utilizing the RTB business model. The company is currently the lead investor in four solar projects across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.

Nexentis Technologies Inc. (NASDAQ: NXTS) filed a prospectus with the SEC to sell 410,998 common shares and an equal number of five-year warrants to raise approximately $2.9 million. Both the shares and warrants are priced at $7.056 per unit. The filing follows the company's recent announcement of a strategic partnership focused on artificial intelligence drug discovery.

The offering details were disclosed in a Form 424B5 prospectus filed with the Securities and Exchange Commission. Nexentis intends to use the capital raised to further its business initiatives, which include the operations of its wholly owned subsidiary, MitoCareX Bio Ltd., and investments in European solar energy projects.

Strategic Partnership

The capital raise coincides with MitoCareX Bio's engagement with Boltz, PBC, an AI research lab. This partnership aims to accelerate the identification of novel small-molecule scaffolds targeting selected solute carrier (SLC) proteins. The initiative combines MitoCareX’s proprietary MITOLINE® algorithm platform with Boltz’s foundation models for predicting biomolecular structure and binding affinity.

Technology and Objectives

The collaboration focuses on strengthening target-specific virtual screening campaigns for challenging transporter proteins. The goal is to improve hit identification for cancers and metabolic diseases. MitoCareX will retain full control over its discovery programs and any candidates advanced using this approach. Boltz’s platform provides a hosted environment combining biomolecular foundation models, managed compute, and scientist-oriented workflows.

Market Performance

Nexentis has a market capitalization of $13.55 million and is down 77.75% over the past 12 months. The stock recently saw significant volatility, surging on the AI drug news before declining after the offering announcement. The company currently trades at about 47.6% of its 52-week range, with a high of $23.80 and a low of $3.38.